Worldwide Intranasal Therapeutics and Drug Delivery Systems Market Distribution to 2035 – Industry Trends and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication, Type of Molecule and Geography: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current market landscape and the likely future potential associated with the intranasal therapeutics and drug delivery systems market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.

Over the past few years, the prevalence of neurological disorders has increased at an annualized rate of 10.9%. Further, the mortality associated with such diseases is projected to account for 12.2% of the global death rate, in 2030. In this context, several research initiatives are underway to identify an approach that allows effective delivery of the target medication directly into the brain.

One key challenge currently faced by researchers is the presence of the complex blood brain barrier (BBB), which hinders the entry of the target drug into the CNS, acting as a significant roadblock in the development of effective treatment modalities. It is worth mentioning that the failure of the ongoing research initiatives can incur losses worth USD 2 billion. As a result, stakeholders in the pharmaceutical domain have shifted their focus towards the use of intranasal treatments, which have demonstrated to be capable of bypassing the blood brain barrier, thereby, delivering the target drug directly into the brain. Clinical studies related to interventional intranasal therapies have increased three-folds over the last decade.

Specifically, post the onset of the COVID-19 pandemic, extensive research focused on intranasal therapeutics is being carried out due to their proven pharmacological value and favorable safety profiles. Notable examples of intranasal COVID-19 targeting drugs that are currently being evaluated across different phases of development include (in alphabetical order) COVIDROPST (Sorrento Therapeutics), DEXANEUROSONET (Biomed IndustriesT) and Zavegepant (Biohaven Pharmaceuticals) .

Despite the several advantages offered by the intranasal route of administration, the delivery of therapies via the aforementioned approach is associated with some challenges, such as mucus and epithelial barriers, low bioavailability of drugs, limited drug absorption and shorter residence time. Most of these concerns can be mitigated via the use of appropriate drug delivery systems. Therefore, several pharmaceutical companies are currently focused on the development of novel drug delivery systems for intranasal therapeutics, since conventional pharmaceutical dosage forms are unable to regulate the rate at which these drugs are delivered to the target site.

At present, close to 40 intranasal drug delivery systems are available in the market. Additionally, USD 5.5 billion was invested in this domain, during 2016-2021. In the same time frame, multiple partnership agreements were established between various stakeholders. Driven by the increasing patient population and the growing demand for such therapeutics, this market is anticipated to witness steady growth in the coming years.

Key Questions Answered

• Who are the key players engaged in the development of intranasal therapeutics and drug delivery systems?
• What are the major therapeutic areas targeted by intranasal therapeutics?
• Which regions represent the maximum research activity related to intranasal therapeutics and drug delivery systems?
• What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
• Who are the key investigators in this domain?
• How is the current and future market opportunity likely to be distributed across key market segments?
• What are the anticipated future trends related to intranasal therapeutics and drug delivery systems?

Companies Mentioned

• Adapt Pharma
• Aegis Therapeutics
• AIM ImmunoTech
• AllianceRx Walgreens Prime
• Altamira Therapeutics
• Altimmune
• AOBiome Therapeutics
• Apricus Biosciences
• Aptar Pharma
• ARS Pharmaceuticals
• ATAI Life Sciences
• AViTA
• Baudax Bio
• BD
• Bespak
• Bharat Biotech
• Biohaven Pharmaceuticals
• Biomed IndustriesT
• BlueWillow Biologics
• Bryn Pharma
• Camargo
• Centre for Human Drug Research
• Codagenix
• Consort Medical
• Copernicus
• Currax Pharmaceuticals
• Cyrano Therapeutics
• Daiichi Sankyo
• Dauntless Pharmaceuticals
• DeVilbiss Healthcare
• Dne Pharma
• Dr. Reddy’s Laboratories
• DynPort Vaccine Company
• Eli Lilly
• ENDECE
• Ferring Pharmaceuticals
• FHI Clinical
• Fiagon
• Glenmark Pharmaceuticals
• Grandpharma (China)
• HealthPartners Institute
• Hikma
• hVIVO
• IDC
• Impel NeuroPharma
• Inexia
• Insight
• Intersect ENT
• Intravacc
• Iowa State University
• Janssen Pharmaceuticals
• Ji Xing Pharmaceuticals
• Kaleo
• Kindeva Drug Delivery
• Kleo Pharmaceuticals
• Kurve Technology
• Lachesis Biosciences
• Levo Therapeutics
• Lonza
• Medigen Vaccine Biologics
• Medline
• Menarini
• Mount Sinai Health System
• Mystic Pharmaceuticals
• Nanomerics
• Nanopharm
• Nasus Pharma
• Nemera
• Neurelis
• Neuronasal
• Noveome Biotherapeutics
• Odyssey Group International
• Olfax Medical
• Opiant Pharmaceuticals
• Optinose
• Orexo
• Oyster Point Pharma
• PaxMedica
• Phil
• Provectus Biopharmaceuticals
• Recordati
• Recro Pharma
• Rocket Science Health
• SaNOtize Research and Development
• Seelos Therapeutics
• Seqirus
• Seurat Therapeutics
• Singota Solutions
• Sinus Dynamics
• SipNose
• SNBL
• Sorrento Therapeutics
• Sosei Heptares
• Summit Biosciences
• Teleflex
• National Institutes of Health
• The University of Tennessee Health Science Center
• Tian Medical
• Tiziana Life Sciences
• UCB
• Univercells
• University of Calgary
• University of Massachusetts
• University of Oxford
• Utrecht University
• Valois
• Veeva Systems
• Vigene Biosciences
• Virpax Pharmaceuticals
• Wageningen Bioveterinary Research
• Yuhan Corporation
• Zeteo Biomedical

For more information about this report visit https://www.researchandmarkets.com/r/4e3xik

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900